Revenue
2009
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Corcept Therapeutics Inc (CORT)
Price$114.89Cached quote
Net income
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M | $353.9M | $306.5M | $251.2M | $159.2M | $81.3M | $50.3M | $26.6M | $10.4M | $3.3M | — | — | $29,000 | — | — | — | — | — | — | — | — | — |
| Gross profit | $748.4M | $664.2M | $475.9M | $396.5M | $360.7M | $348.3M | $301.0M | $246.0M | $155.6M | $79.3M | $48.9M | $25.7M | $10.2M | $3.2M | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 98.30% | 98.39% | 98.66% | 98.66% | 98.56% | 98.42% | 98.20% | 97.92% | 97.77% | 97.47% | 97.29% | 96.68% | 98.62% | 97.25% | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M | $114.8M | $89.0M | $75.2M | $40.4M | $23.8M | $15.4M | $18.4M | $20.5M | $14.1M | $21.0M | $18.9M | $14.4M | — | — | — | — | — | — | — | — | — |
| Operating expenses | $716.6M | $538.1M | $375.1M | $289.2M | $241.5M | $225.7M | $194.9M | $161.8M | $106.3M | $71.1M | $52.4M | $54.2M | $51.9M | $39.6M | $32.3M | $27.4M | $20.3M | — | — | — | — | — | — | — | — | — |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M | $128.2M | $111.6M | $89.5M | $52.9M | $10.2M | −$3.4M | −$27.6M | −$41.5M | −$36.3M | −$32.3M | −$27.4M | −$20.3M | — | — | — | — | — | — | — | — | — |
| Operating margin | 5.88% | 20.29% | 22.24% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.52% | −6.85% | −104.02% | −400.66% | −1,096.82% | — | — | −69,827.59% | — | — | — | — | — | — | — | — | — |
| EBITDA | $45.9M | $137.7M | $108.3M | $113.9M | $125.5M | $128.7M | $112.3M | $89.7M | $53.0M | $10.3M | −$3.3M | −$27.5M | −$41.4M | −$36.2M | −$32.3M | −$27.4M | −$20.2M | — | — | — | — | — | — | — | — | — |
| EBITDA margin | 6.03% | 20.41% | 22.46% | 28.34% | 34.31% | 36.38% | 36.64% | 35.71% | 33.27% | 12.62% | −6.54% | −103.49% | −399.94% | −1,096.01% | — | — | −69,793.10% | — | — | — | — | — | — | — | — | — |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M | $106.0M | $94.2M | $75.4M | $129.1M | $8.1M | −$6.4M | −$31.4M | −$46.0M | −$38.0M | −$32.4M | −$26.0M | −$20.2M | −$20.1M | −$11.6M | −$24.9M | −$20.1M | −$15.5M | −$9.8M | −$18.5M | −$7.5M | −$1.8M |
| Net profit margin | 13.09% | 20.92% | 22.00% | 25.24% | 30.74% | 29.96% | 30.73% | 30.01% | 81.11% | 10.01% | −12.74% | −118.20% | −444.25% | −1,150.53% | — | — | −69,537.93% | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 | $0.82 | $0.65 | $1.14 | $0.07 | -$0.06 | -$0.31 | -$0.46 | -$0.41 | -$0.39 | -$0.38 | -$0.38 | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | -$0.06 | -$0.31 | -$0.46 | -$0.41 | -$0.39 | -$0.38 | -$0.38 | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
11.52%of listed shares
BlackRock, Inc.12.43M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 11.52%12.43M shares |
INGALLS & SNYDER LLC | 7.35%7.93M shares |
BAKER G LEONARD JR | ≈5.14%5.55M shares |
RENAISSANCE TECHNOLOGIES LLC | 4.88%5.26M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.67%5.04M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.87%4.17M shares |
Parallel Advisors, LLC | 3.67%3.96M shares |
FMR LLC | 3.09%3.34M shares |
STATE STREET CORP | 3.04%3.28M shares |
BELANOFF JOSEPH K | ≈2.66%2.87M shares |
AQR CAPITAL MANAGEMENT LLC | 2.39%2.58M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.35%2.53M shares |
FIRST TRUST ADVISORS LP | 1.70%1.83M shares |
TANG CAPITAL MANAGEMENT LLC | 1.39%1.5M shares |
WILSON JAMES N | ≈1.38%1.49M shares |
UBS Group AG | 1.28%1.38M shares |
DIMENSIONAL FUND ADVISORS LP | 1.22%1.32M shares |
MAHONEY DAVID L | ≈1.17%1.26M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.07%1.16M shares |
MORGAN STANLEY | 1.05%1.14M shares |
Percentages use 107.92M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 | MAHONEY DAVID LDirector | SellCommon Stock · indirect | 20.0K | $84.53 | $1.69M | 26.1K |
| Jun 16, 2026Form 4 · 10b5-1 | WILSON JAMES NDirector | SellCommon Stock · indirect | 5.8K | $83.57 | $486.6K | 1.09M |
| Jun 16, 2026Form 4 · 10b5-1 | WILSON JAMES NDirector | SellCommon Stock · indirect | 4.2K | $82.69 | $345.4K | 1.10M |
| Jun 15, 2026Form 4 · 10b5-1 | Mokari AtabakChief Financial Officer | SellCommon Stock | 2 | $82.45 | $164.90 | 16.1K |
| Jun 15, 2026Form 4 · 10b5-1 | Mokari AtabakChief Financial Officer | SellCommon Stock | 19.5K | $81.81 | $1.59M | 16.1K |
Community posts
Corcept receives positive European recommendation for ovarian-cancer therapy
European drug advisers recommended approval of Corcept’s ($CORT) relacorilant, to be marketed as Lifyorli, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The positive opinion from the Committee for Medicinal Produ ...
